Age De-escalation Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of a Late Liver Stage-arresting, Replication-competent Plasmodium Falciparum Sporozoite Vaccine (Sanaria® PfSPZ-LARC2 Vaccine) Administered by Direct Venous Inoculation to Malaria-exposed Adults and Children in Burkina Faso
Latest Information Update: 15 Apr 2025
At a glance
- Drugs Malaria vaccine live attenuated-Sanaria (Primary)
- Indications Falciparum malaria
- Focus Adverse reactions; First in man
- Sponsors Sanaria
Most Recent Events
- 09 Apr 2025 Planned primary completion date changed from 1 Oct 2025 to 1 Nov 2025.
- 09 Apr 2025 Status changed from not yet recruiting to recruiting.
- 13 Feb 2025 Planned End Date changed from 1 Sep 2025 to 1 Dec 2025.